A venture capital firm founded in 2016 with offices in USA and China invests exclusively in healthcare companies (therapeutics, medical devices, digital health, and healthcare services). The firm typically invests $1-5M (USD) of equity capital with the ability to make follow-on investment. The fund aims to make at least 5 investments per year, but this is not a fixed number. In general, the firm participates in seed, series A and series B funding rounds. The firm looks at companies of all parts of the world and has a strong preference for companies that have market opportunities in the US, Europe and China. The firm’s China office can provide companies with the resources they need for successful market entry in Asian markets.
The firm looks at all sectors pertaining to healthcare, including biotech therapeutics, R&D services, diagnostics, medical devices, and digital health. While the firm’s focus is in early-stage companies, it takes a very opportunistic viewpoint. In therapeutics, the firm will look at products of all stages from pre-clinical to phase III, and is open to all indications. In terms of medical devices, the firm will consider both 510k and PMA devices. In addition, the firm will also consider products that are already on the market.
The firm is open to both public and private companies, and expects them to have an experienced management team with a strong exit strategy. The firm requires a board seat in all portfolio companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply